Literature DB >> 11934812

Mutations inducing divergent shifts of constitutive activity reveal different modes of binding among catecholamine analogues to the beta(2)-adrenergic receptor.

Renata Del Carmine1, Caterina Ambrosio, Maria Sbraccia, Susanna Cotecchia, Adriaan P Ijzerman, Tommaso Costa.   

Abstract

1. We compared the changes in binding energy generated by two mutations that shift in divergent directions the constitutive activity of the human beta(2) adrenergic receptor (beta(2)AR). 2. A constitutively activating mutant (CAM) and the double alanine replacement (AA mutant) of catechol-binding serines (S204A, S207A) in helix 5 were stably expressed in CHO cell lines, and used to measure the binding affinities of more than 40 adrenergic ligands. Moreover, the efficacy of the same group of compounds was determined as intrinsic activity for maximal adenylyl cyclase stimulation in wild-type beta(2)AR. 3. Although the two mutations had opposite effects on ligand affinity, the extents of change were in both cases largely correlated with the degree of ligand efficacy. This was particularly evident if the extra loss of binding energy due to hydrogen bond deletion in the AA mutant was taken into account. Thus the data demonstrate that there is an overall linkage between the configuration of the binding pocket and the intrinsic equilibrium between active and inactive receptor forms. 4. We also found that AA mutation-induced affinity changes for catecholamine congeners gradually lacking ethanolamine substituents were linearly correlated to the loss of affinity that such modifications of the ligand cause for wild-type receptor. This indicates that the strength of bonds between catechol ring and helix 5 is critically dependent on the rest of interactions of the beta-ethanolamine tail with other residues of the beta(2)-AR binding pocket.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11934812      PMCID: PMC1573288          DOI: 10.1038/sj.bjp.0704622

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  13 in total

1.  Constitutive activation of the alpha 1B-adrenergic receptor by all amino acid substitutions at a single site. Evidence for a region which constrains receptor activation.

Authors:  M A Kjelsberg; S Cotecchia; J Ostrowski; M G Caron; R J Lefkowitz
Journal:  J Biol Chem       Date:  1992-01-25       Impact factor: 5.157

2.  A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty.

Authors:  A Shenker; L Laue; S Kosugi; J J Merendino; T Minegishi; G B Cutler
Journal:  Nature       Date:  1993-10-14       Impact factor: 49.962

3.  Catechol-binding serines of beta(2)-adrenergic receptors control the equilibrium between active and inactive receptor states.

Authors:  C Ambrosio; P Molinari; S Cotecchia; T Costa
Journal:  Mol Pharmacol       Date:  2000-01       Impact factor: 4.436

4.  Study of interaction between agonists and asn293 in helix VI of human beta(2)-adrenergic receptor.

Authors:  H M Zuurmond; J Hessling; K Blüml; M Lohse; A P Ijzerman
Journal:  Mol Pharmacol       Date:  1999-11       Impact factor: 4.436

5.  Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5.

Authors:  D A Shapiro; K Kristiansen; W K Kroeze; B L Roth
Journal:  Mol Pharmacol       Date:  2000-11       Impact factor: 4.436

6.  Constitutively active mutants of the alpha 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation.

Authors:  A Scheer; F Fanelli; T Costa; P G De Benedetti; S Cotecchia
Journal:  EMBO J       Date:  1996-07-15       Impact factor: 11.598

7.  The forgotten serine. A critical role for Ser-2035.42 in ligand binding to and activation of the beta 2-adrenergic receptor.

Authors:  G Liapakis; J A Ballesteros; S Papachristou; W C Chan; X Chen; J A Javitch
Journal:  J Biol Chem       Date:  2000-12-01       Impact factor: 5.157

8.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor.

Authors:  C D Strader; M R Candelore; W S Hill; I S Sigal; R A Dixon
Journal:  J Biol Chem       Date:  1989-08-15       Impact factor: 5.157

9.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function.

Authors:  C D Strader; I S Sigal; M R Candelore; E Rands; W S Hill; R A Dixon
Journal:  J Biol Chem       Date:  1988-07-25       Impact factor: 5.157

10.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor.

Authors:  K Wieland; H M Zuurmond; C Krasel; A P Ijzerman; M J Lohse
Journal:  Proc Natl Acad Sci U S A       Date:  1996-08-20       Impact factor: 11.205

View more
  7 in total

1.  Comparative pharmacology of human beta-adrenergic receptor subtypes--characterization of stably transfected receptors in CHO cells.

Authors:  C Hoffmann; M R Leitz; S Oberdorf-Maass; M J Lohse; K-N Klotz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-01-17       Impact factor: 3.000

2.  Quantifying ligand bias at seven-transmembrane receptors.

Authors:  Sudarshan Rajagopal; Seungkirl Ahn; David H Rominger; William Gowen-MacDonald; Christopher M Lam; Scott M Dewire; Jonathan D Violin; Robert J Lefkowitz
Journal:  Mol Pharmacol       Date:  2011-05-24       Impact factor: 4.436

3.  G Protein-Coupled Receptor Endocytosis Confers Uniformity in Responses to Chemically Distinct Ligands.

Authors:  Nikoleta G Tsvetanova; Michelle Trester-Zedlitz; Billy W Newton; Daniel P Riordan; Aparna B Sundaram; Jeffrey R Johnson; Nevan J Krogan; Mark von Zastrow
Journal:  Mol Pharmacol       Date:  2016-11-22       Impact factor: 4.436

4.  Analysis of L-DOPA and droxidopa binding to human β2-adrenergic receptor.

Authors:  Akash Deep Biswas; Andrea Catte; Giordano Mancini; Vincenzo Barone
Journal:  Biophys J       Date:  2021-11-10       Impact factor: 4.033

5.  Analysis of full and partial agonists binding to beta2-adrenergic receptor suggests a role of transmembrane helix V in agonist-specific conformational changes.

Authors:  Vsevolod Katritch; Kimberly A Reynolds; Vadim Cherezov; Michael A Hanson; Christopher B Roth; Mark Yeager; Ruben Abagyan
Journal:  J Mol Recognit       Date:  2009 Jul-Aug       Impact factor: 2.137

6.  Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway.

Authors:  Alicja J Copik; Aleksander Baldys; Khanh Nguyen; Sunil Sahdeo; Hoangdung Ho; Alan Kosaka; Paul J Dietrich; Bill Fitch; John R Raymond; Anthony P D W Ford; Donald Button; Marcos E Milla
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

7.  Agonist binding by the β2-adrenergic receptor: an effect of receptor conformation on ligand association-dissociation characteristics.

Authors:  Anita Plazinska; Wojciech Plazinski; Krzysztof Jozwiak
Journal:  Eur Biophys J       Date:  2015-03-01       Impact factor: 1.733

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.